|
| Study ID | Study groups | Number of patients | Age, mean (SD) | Sex (male), no. (%) | Race, no. (%) | Disease duration, mean (SD), y | Investigator’s global assessment (IGA) grade, no. (%) | Eczema area and severity index (EASI) score, mean (SD) | % body surface area (BSA) affected, mean (SD) | Pruritus numeric rating scale (NRS) score, mean (SD) | Scoring atopic dermatitis (SCORAD), mean (SD) | Pruritus and symptoms assessment for atopic dermatitis (PSAAD), mean (SD) | Patient-oriented eczema measure (POEM), mean (SD) | Dermatology life quality index (DLQI), mean (SD), patients | Children’s dermatology life quality index (CDLQI), mean (SD), patients | Previous medications for AD |
| White | Black | Asian | Others | Not reported | Moderate (grade 3) | Severe (grade 4) |
|
| Gooderham 2019 | Abrocitinib
10 mg
Abrocitinib
30 mg
Abrocitinib
100 mg
Abrocitinib
200 mg
Placebo | 49
51
56
55
56 | 44.3
(15.9)
37.6
(15.9)
41.1
(15.6)
38.7
(17.6)
42.6
(15.1) | 21 (42.9)
22 (43.1)
31 (55.4)
28 (50.9)
21 (37.5) | 38 (77.6)
39 (76.5)
40 (71.4)
37 (67.3)
40 (71.4) | 5 (10.2)
4 (7.8)
7 (12.5)
13 (23.6)
10 (17.9) | 5 (10.2
5 (9.8)
)
8 (14.3)
5 (9.1)
4 (7.1) | 1 (2.0)
3 (5.9)
1 (1.8)
0 (0)
2 (3.6) | — | 30.3 (14.7)
20.5 (16.35)
23.8 (16.4)
19.6
(16.73)
25.6 (16.5) | 27 (55.1)
28 (56.0)
29 (52.7)
34 (63.0)
34 (61.8) | 22 (44.9)
22 (44.0)
26 (47.3
20 (37.0))
21 (38.2) | 28.1 (13.1)
22.1 (10.7)
26.7 (11.8)
24.6 (13.5)
25.4 (12.9) | 44.2 (22.7)
34.1 (20.8)
41.9 (22.3)
38.0 (23.3)
40.1 (22.3) | 7.6 (1.7)
7.6 (1.9)
7.4 (2.2)
6.9 (2.7)
7.6 (1.8) | 65.3 (13.2)
62.4 (13.0)
65.4 (13.7)
62.7 (13.7)
65.0 (12.1) | — | — | — | — | Topical corticosteroids or topical calcineurin inhibitors |
|
| Silverberg 2020 | Abrocitinib
100 mg
Abrocitinib
200 mg
Placebo | 158
155
78 | 37.4
(15.8)
33.5
(14.7)
33.4
(13.8) | 94 (59.5)
88 (56.8)
47 (60.3) | 101(63.9)
91 (58.7)
40 (51.3) | 9 (5.7)
6 (3.9)
6 (7.7) | 46 (29.1)
54 (34.8)
29 (37.2) | 1 (0.6)
2 (1.3)
1 (1.3) | 1 (0.6)
2 (1.3)
2 (2.6) | 21.1 (14.8)
20.5 (14.8)
21.7 (14.3) | 107 (67.7)
106 (68.4)
52 (66.7) | 51 (32.3)
49 (31.6)
26 (33.3) | 28.4 (11.2)
29.0 (12.4)
28.0 (10.2) | 48.7 (21.4)
47.7 (22.3)
48.2 (20.8) | 7.1 (1.6)
7.0 (1.6)
6.7 (1.9) | 63.8 (11.4)
64.1 (13.1)
64.3 (12.4) | 5.4 (2.1)
5.2 (2.0)
5.1 (2.1) | 20.9 (5.7)
19.7 (5.7)
19.2 (5.5) | 15.4 (7.3), 140
14.8 (6.0), 139
15.0 (7.1), 70 | 13.8 (5.8), 16
12.9 (5.7), 15
10.1 (3.8), 8 | Anti-inflammatory topical agents alone (226), systemic agents and/or topical agents (162), dupilumab (14) |
|
| Simpson 2020 | Abrocitinib
100 mg
Abrocitinib
200 mg
Placebo | 156
154
77 | 32·6
(15·4)
33·0
(17·4)
31·5
(14·4) | 90 (58)
81 (53)
49 (64) | 113 (72)
104 (68)
62 (81) | 15 (10)
11 (7)
6 (8) | 26 (17)
26 (17)
6 (8) | 2 (1)
11 (7)
2 (3) | 0 (0)
2 (1%)
1 (1%) | 24·9 (16·1)
22·7 (14·5)
22·5 (14·4) | 92 (59)
91 (59)
46 (60) | 64 (41)
63 (41)
31 (40) | 31·3 (13·6)
30·6 (14·1)
28·7 (12·5) | 50·8 (23·4)
49·9 (24·4)
47·4 (22·7) | 6·9 (2·0)
7·1 (1·9)
7·0 (1·8) | 67·1 (13·7)
64·3 (13·1)
64·5 (13·2) | 5·3 (2·3)
5·4 (2·1)
5·5 (2·0) | 19·5 (6·5)
19·6 (5·9)
19·9 (6·1) | 14·6 (6·5), 121
14·6 (6·8), 119
13·9 (7·3), 60 | 11·7 (6·6), 32 13·2
(5·5), 32
13·6 (7·0), 16 | Anti-inflammatory topical agents alone (185), systemic agents and/or topical agents (187), dupilumab (30) |
|
| Pfizer (JADE compare trial) 2021 | First 16 weeks | Abrocitinib
100 mg
Abrocitinib
200 mg
-Placebo
Dupilumab 300 mg | 238
226
131
242 | −(224)
18–65
(14) >=65
−(211) 18–65
(15) >=65
−(121)
18–65
(10) >=65
−(227)
18–65
(15) >=65 | 120 (50.4)
104 (46)
77 (58.8)
108
(44.6) | 182 (76.5)
161 (71.2)
87 (66.4)
176 (72.7) | 6 (2.5)
9 (4)
6 (4.6)
14 (5.8) | 48 (20.2)
53 (23.5)
31 (23.7)
46 (19.0) | 2 (0.0084)
2 (0.0088)
4 (0.031)
4 (0.0165) | 0 (0.0)
1 (0.4)
3 (2.3)
2 (0.8) | — | — | — | — | — | — | — | — | — | — | — | — |
| Final 4 weeks (16-20) | -Abrocitinib
100 mg
(after 16 weeks abrocitinib 100 mg)
-Abrocitinib
200 mg
(after 16 weeks placebo)
Abrocitinib
100 mg
(after 16 weeks
placebo) Abrocitinib
200 mg
(after 16 weeks placebo)
Placebo
(after 16 weeks dupilumab) | 238
226
60
57
242 | −(224) 18–65
(14) >=65
−(121) 18–65
(10) >=65
−(121)
18–65
(10) >=65
−(227)
18–65
(15) >=65 | 120(50.4)
104(46)
77 (58.8)
77 (58.8)
108
(44.6) | 182 (76.5)
161 (71.2)
87 (66.4)
87 (66.4)
176(72.7) | 6 (2.5)
9 (4)
6 (4.6)
6 (4.6)
14 (5.8) | 48 (20.2)
53 (23.5)
31 (23.7)
31 (23.7)
46 (19.0) | 2 (0.0084)
2 (0.0088)
4 (0.031)
4 (0.031)
4 (0.0165) | 0 (0.0)
1 (0.4)
3 (2.3)
3 (2.3)
2 (0.8) | — | — | — | — | — | — | — | — | — | — | — | — |
|
